{"id":"trivalent-influenza-vaccine-a","safety":{"commonSideEffects":[{"rate":"10–30","effect":"Injection site pain, redness, or swelling"},{"rate":"5–15","effect":"Myalgia"},{"rate":"5–10","effect":"Headache"},{"rate":"1–5","effect":"Fever"},{"rate":"5–10","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"The vaccine contains inactivated viral antigens from three influenza virus strains, which are presented to the immune system to generate humoral and cellular immune responses. This priming allows the vaccinated individual to mount a rapid and effective antibody response upon exposure to circulating influenza viruses, reducing infection risk and disease severity.","oneSentence":"A trivalent inactivated influenza vaccine that stimulates the immune system to produce antibodies against three strains of influenza virus (typically two A strains and one B strain).","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:54:35.037Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seasonal influenza prevention in adults and children"}]},"trialDetails":[{"nctId":"NCT07493460","phase":"PHASE4","title":"Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-08-26","conditions":"Immunology, Healthy Adults","enrollment":25},{"nctId":"NCT07291635","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine","status":"RECRUITING","sponsor":"Aramis Biotechnologies Inc.","startDate":"2026-02-25","conditions":"Influenza","enrollment":728},{"nctId":"NCT06087640","phase":"PHASE3","title":"A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seqirus","startDate":"2023-10-23","conditions":"Influenza, Human","enrollment":35800},{"nctId":"NCT07282795","phase":"","title":"Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled Syringe","status":"NOT_YET_RECRUITING","sponsor":"Sanofi","startDate":"2026-03-31","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":670},{"nctId":"NCT06850051","phase":"PHASE1","title":"A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age.","status":"COMPLETED","sponsor":"Sanofi","startDate":"2025-03-19","conditions":"Healthy Volunteers, Influenza Vaccination, Respiratory Syncytial Virus Vaccination","enrollment":270},{"nctId":"NCT02518555","phase":"PHASE2","title":"Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jennifer Woyach","startDate":"2016-01-12","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":42},{"nctId":"NCT06641180","phase":"PHASE3","title":"Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-11-04","conditions":"Influenza","enrollment":1180},{"nctId":"NCT07192458","phase":"PHASE2","title":"High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2025-09-17","conditions":"Immunization; Infection|Transplantation Infection|Influenza, Influenza","enrollment":60},{"nctId":"NCT06664151","phase":"EARLY_PHASE1","title":"A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-11-26","conditions":"Skin Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Cutaneous Squamous Cell Cancer","enrollment":25},{"nctId":"NCT05779020","phase":"PHASE3","title":"Immunogenicity and Safety of Butantan Quadrivalent Influenza Vaccine (Split Virion, Inactivated) in Infants and Children .","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2023-04-25","conditions":"Influenza, Human","enrollment":1373},{"nctId":"NCT04210349","phase":"PHASE3","title":"Study of Shenzhen Quadrivalent Inactivated Influenza Vaccine Versus the Shenzhen Trivalent Inactivated Influenza Vaccine in Chinese Subjects From 6 Months of Age","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-01-09","conditions":"Influenza","enrollment":7106},{"nctId":"NCT01773928","phase":"PHASE3","title":"Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived)","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2013-01","conditions":"Influenza","enrollment":1928},{"nctId":"NCT06507553","phase":"PHASE1","title":"Study of Influenza Vaccines Containing an Additional H3 Antigen in Healthy Adult Participants 18 to 49 Years of Age and 60 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-08-12","conditions":"Influenza, Healthy Volunteers","enrollment":400},{"nctId":"NCT06602024","phase":"PHASE3","title":"A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2024-09-16","conditions":"Seasonal Influenza","enrollment":40817},{"nctId":"NCT06049927","phase":"PHASE3","title":"A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2023-09-16","conditions":"Seasonal Influenza","enrollment":3300},{"nctId":"NCT06291857","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novavax","startDate":"2024-12-09","conditions":"COVID-19","enrollment":9320},{"nctId":"NCT05663463","phase":"NA","title":"Seasonal Influenza Vaccine High Dose Boosting in Solid Organ Transplant Recipients","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2023-09-11","conditions":"Solid Organ Transplant","enrollment":74},{"nctId":"NCT06744205","phase":"PHASE1, PHASE2","title":"A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2025-01-06","conditions":"Influenza, Healthy Volunteers","enrollment":1162},{"nctId":"NCT06987942","phase":"PHASE4","title":"Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vaccine (Split Virion)","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2024-09-21","conditions":"Varicella, Influenza Vaccine","enrollment":899},{"nctId":"NCT06482359","phase":"PHASE2, PHASE3","title":"Lot Consistency Study of COVID-19 and Influenza Combination Vaccine","status":"WITHDRAWN","sponsor":"Novavax","startDate":"2025-02-01","conditions":"COVID-19, Influenza","enrollment":""},{"nctId":"NCT06485752","phase":"PHASE2, PHASE3","title":"Phase 3 Lot Consistency Study of Trivalent Hemagglutinin Nanoparticle Influenza Vaccine","status":"WITHDRAWN","sponsor":"Novavax","startDate":"2024-11","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04080531","phase":"PHASE4","title":"Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-10-18","conditions":"Plasma Cell Neoplasm","enrollment":165},{"nctId":"NCT03927131","phase":"PHASE3","title":"Safety and Immunogenicity of the Butantan Quadrivalent Influenza Vaccine","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2021-05-12","conditions":"Influenza, Human","enrollment":5822},{"nctId":"NCT03312699","phase":"PHASE1","title":"Effects of Aging on Primary and Secondary Vaccine Responses","status":"COMPLETED","sponsor":"Stanford University","startDate":"2017-09-19","conditions":"Influenza, Hepatitis A, Typhoid","enrollment":54},{"nctId":"NCT03849560","phase":"PHASE2, PHASE3","title":"Safety, Reactogenicity, Immunogenicity, Efficacy of Influenza Vaccines Grippol® Quadri and Grippol® Plus in Volunteers","status":"COMPLETED","sponsor":"NPO Petrovax","startDate":"2016-11","conditions":"Influenza","enrollment":612},{"nctId":"NCT01538940","phase":"PHASE4","title":"Immunogenicity of Influenza Vaccines in HIV-infected Persons in Thailand","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2011-11-01","conditions":"Influenza","enrollment":415},{"nctId":"NCT02936180","phase":"PHASE4","title":"Standard Versus High Dose Inactivated Influenza Vaccine in RA","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2016-10","conditions":"Rheumatoid Arthritis","enrollment":279},{"nctId":"NCT05245552","phase":"PHASE3","title":"A Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2022-08-08","conditions":"Seasonal Influenza","enrollment":217},{"nctId":"NCT00630331","phase":"PHASE3","title":"Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-10","conditions":"Influenza","enrollment":11404},{"nctId":"NCT06385821","phase":"PHASE3","title":"A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus","status":"COMPLETED","sponsor":"NPO Petrovax","startDate":"2022-09-21","conditions":"Influenza, Influenza A, Influenza, Human","enrollment":824},{"nctId":"NCT06286488","phase":"PHASE4","title":"Effectiveness and Tolerability of Influenza Vaccine in Patients at Risk for Severe and Complicated Influenza","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical University of Warsaw","startDate":"2020-09-15","conditions":"Influenza, Obesity, Pregnancy; Infection","enrollment":1500},{"nctId":"NCT03777163","phase":"PHASE4","title":"Safety and Immunogenicity of the Butantan Institute Influenza Vaccine Compared to Sanofi Pasteur Influenza Vaccine","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2019-04-22","conditions":"Influenza","enrollment":632},{"nctId":"NCT06252051","phase":"PHASE4","title":"Effectiveness of Trivalent Influenza Vaccine (TIV) in Type 2 Diabetes Mellitus (T2DM) Patients With and Without Complications of Chronic Kidney Disease (CKD)","status":"COMPLETED","sponsor":"Universitas Padjadjaran","startDate":"2021-01-05","conditions":"Influenza, Vaccine Reaction, Diabetes Mellitus","enrollment":76},{"nctId":"NCT03744104","phase":"PHASE3","title":"A Clinical Trial of A Quadrivalent Influenza Vaccine","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2018-10-11","conditions":"Influenza","enrollment":2688},{"nctId":"NCT04363359","phase":"PHASE2","title":"Clinical Trial of Quadrivalent Influenza Virus Split Vaccine","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2020-01-15","conditions":"Influenza","enrollment":1980},{"nctId":"NCT02529904","phase":"PHASE2","title":"ADITEC FLU 2 STUDY: Understanding the Genetics Basis for Immune Responses to Flu Vaccines in Children and Adults","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-08","conditions":"Influenza","enrollment":120},{"nctId":"NCT02385123","phase":"PHASE4","title":"Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy Volunteers","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-04-01","conditions":"Influenza, Influenza Immunisation","enrollment":60},{"nctId":"NCT02485639","phase":"PHASE4","title":"Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza Vaccination","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-12-23","conditions":"Influenza, Influenza Immunisation","enrollment":27},{"nctId":"NCT02677493","phase":"PHASE3","title":"Study to Evaluate the Immunogenicity and Safety of 'IL-YANG Quadrivalent Influenza Vaccine Inj.'","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2015-10","conditions":"Influenza","enrollment":1794},{"nctId":"NCT04695717","phase":"PHASE3","title":"This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam","status":"COMPLETED","sponsor":"Vietnam Military Medical University","startDate":"2020-09-05","conditions":"Influenza","enrollment":864},{"nctId":"NCT04484532","phase":"EARLY_PHASE1","title":"Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2017-10-17","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":130},{"nctId":"NCT01344057","phase":"PHASE2","title":"Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-05","conditions":"Seasonal Influenza","enrollment":63},{"nctId":"NCT03669627","phase":"PHASE2","title":"CT18 Infant Influenza Priming Study in Vaccine Naive Infants","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2018-11-01","conditions":"Influenza","enrollment":159},{"nctId":"NCT01964989","phase":"PHASE3","title":"Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.","status":"COMPLETED","sponsor":"Seqirus","startDate":"2013-11","conditions":"Influenza Virus","enrollment":10644},{"nctId":"NCT03293498","phase":"PHASE1, PHASE2","title":"Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)","status":"COMPLETED","sponsor":"Novavax","startDate":"2017-09-18","conditions":"Influenza","enrollment":330},{"nctId":"NCT02523287","phase":"PHASE4","title":"Placebo Controlled Study to Generate Data Characterising Clinical Events, Physiological Responses and Immune Responses","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2014-10-02","conditions":"Safety Markers of Adjuvanted Influenza Vaccine","enrollment":240},{"nctId":"NCT03658629","phase":"PHASE2","title":"Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults","status":"TERMINATED","sponsor":"Novavax","startDate":"2018-09-24","conditions":"Influenza, Human","enrollment":1375},{"nctId":"NCT03438487","phase":"","title":"Flucelvax (TIVc or QIVc) Pregnancy Registry","status":"COMPLETED","sponsor":"Seqirus","startDate":"2017-09-01","conditions":"Influenza, Human, Pregnancy, Birth Defect","enrollment":692},{"nctId":"NCT01676402","phase":"PHASE1","title":"Seasonal Influenza HA DNA With Trivalent Inactivated Vaccine (TIV) Administered ID or IM in Healthy Adults 18-70 Years","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-08","conditions":"Influenza","enrollment":316},{"nctId":"NCT04548518","phase":"PHASE3","title":"Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Split Virion Influenza Vaccine, in Healthy Thai Elderly","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2020-08-03","conditions":"Influenza","enrollment":816},{"nctId":"NCT03704740","phase":"PHASE3","title":"Immunogenicity and Safety of NBP607-QIV Compared to Agrippal in Children Aged 6 to 35 Months","status":"COMPLETED","sponsor":"SK Bioscience Co., Ltd.","startDate":"2018-10-25","conditions":"Influenza","enrollment":676},{"nctId":"NCT03344029","phase":"PHASE4","title":"Immunogenicity and Safety of the Shenzhen Trivalent Inactivated Influenza Vaccine Versus a Trivalent Influenza Vaccine Comparator in Chinese Subjects 18 to 59 Years","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-11-03","conditions":"Influenza, Flu","enrollment":1600},{"nctId":"NCT03282240","phase":"PHASE3","title":"Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2017-09-08","conditions":"Influenza","enrollment":2670},{"nctId":"NCT04833101","phase":"PHASE4","title":"Study on Heterologous Prime-boost of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2021-04-07","conditions":"COVID-19","enrollment":120},{"nctId":"NCT00539981","phase":"PHASE3","title":"Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-09-15","conditions":"Influenza","enrollment":4648},{"nctId":"NCT02550197","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Given by Intramuscular Route in Subjects Aged 18 to 60 Years","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2015-09","conditions":"Influenza","enrollment":300},{"nctId":"NCT03068949","phase":"PHASE4","title":"Comparison of Three Licensed Influenza Vaccines","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2015-10-28","conditions":"Influenza","enrollment":413},{"nctId":"NCT02747407","phase":"","title":"Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2016-05","conditions":"Astrocytoma, Glioma, Oligodendroglioma","enrollment":55},{"nctId":"NCT00461981","phase":"PHASE2","title":"A Phase 2 Study to Evaluate Immune Responses of FluMist®","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2007-05","conditions":"Influenza Vaccine","enrollment":101},{"nctId":"NCT00192192","phase":"PHASE3","title":"Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2000-11","conditions":"Influenza","enrollment":20},{"nctId":"NCT00192231","phase":"PHASE3","title":"Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine,(CAIV-T)","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2001-04","conditions":"Influenza","enrollment":120},{"nctId":"NCT00128167","phase":"PHASE3","title":"Trivalent, Live, Cold Adapted Influenza Vaccine (CAIV-T) Against Inactivated Influenza Vaccine (TIV) in Children 6-59 Months of Age","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2004-10","conditions":"Influenza","enrollment":8500},{"nctId":"NCT00192348","phase":"PHASE1","title":"A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine,(CAIV-T) in Healthy Infants","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2002-05","conditions":"Healthy","enrollment":120},{"nctId":"NCT00987350","phase":"PHASE4","title":"Safety Study of Seasonal Influenza Vaccine by Jet Injection","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2010-01","conditions":"Healthy Adults","enrollment":60},{"nctId":"NCT04143451","phase":"PHASE3","title":"Intradermal Influenza Vaccine With Topical Imiquimod in Elderly and Chronic Illness Patients","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2019-10-23","conditions":"Influenza","enrollment":4000},{"nctId":"NCT00841763","phase":"PHASE3","title":"Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-10","conditions":"Pandemic Influenza Disease","enrollment":3647},{"nctId":"NCT01863849","phase":"PHASE4","title":"Tolerability and Immunogenicity Study of Fluval AB Suspension for Injection","status":"COMPLETED","sponsor":"Fluart Innovative Vaccine Ltd, Hungary","startDate":"2013-08-22","conditions":"Influenza Prophylaxis","enrollment":120},{"nctId":"NCT02387294","phase":"PHASE3","title":"Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection for Children and Adolescents","status":"COMPLETED","sponsor":"Fluart Innovative Vaccine Ltd, Hungary","startDate":"2014-10","conditions":"Human Influenza","enrollment":120},{"nctId":"NCT02933723","phase":"NA","title":"Immunogenicity of Influenza Vaccine in Long Term Care","status":"UNKNOWN","sponsor":"Insight Therapeutics, LLC","startDate":"2016-10","conditions":"Influenza","enrollment":200},{"nctId":"NCT03448705","phase":"PHASE1","title":"Safety of 4Fluart ID Suspension for Injection in Adult Subjects","status":"COMPLETED","sponsor":"Fluart Innovative Vaccine Ltd, Hungary","startDate":"2018-01-31","conditions":"Human Influenza","enrollment":36},{"nctId":"NCT00283283","phase":"PHASE2","title":"Comparison of Full-dose Flu Vaccine to Half-dose Flu Vaccine","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2004-11","conditions":"Influenza","enrollment":1316},{"nctId":"NCT03699839","phase":"PHASE2, PHASE3","title":"Reducing the Burden of Influenza After Solid-Organ Transplantation","status":"COMPLETED","sponsor":"Oriol Manuel","startDate":"2018-10-26","conditions":"Influenza, Organ Transplantation","enrollment":619},{"nctId":"NCT01157702","phase":"PHASE3","title":"Yearly Strain Variation Study, 2010/2011","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2010-07","conditions":"Influenza, Seasonal Influenza","enrollment":110},{"nctId":"NCT04551248","phase":"","title":"Post-marketing Safety Evaluation of Pneumococcal Vaccines Among Children and Elderly Adults.","status":"UNKNOWN","sponsor":"Sungkyunkwan University","startDate":"2021-08-01","conditions":"Pneumococcal Vaccine Adverse Reaction","enrollment":1000000},{"nctId":"NCT04515368","phase":"NA","title":"A Pilot Clinical Study of PET Scanning in Evaluation of Vaccine Reactogenicity","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2016-06-10","conditions":"Positron-Emission Tomography, Immunization Reaction","enrollment":54},{"nctId":"NCT03314662","phase":"PHASE3","title":"Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2017-10-17","conditions":"Influenza, Human","enrollment":1778},{"nctId":"NCT02467842","phase":"PHASE3","title":"Immunogenicity and Safety of Quadrivalent Influenza Vaccine (NBP607-QIV) in Adults and Elderly Subjects","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2014-10","conditions":"Influenza","enrollment":1503},{"nctId":"NCT04355806","phase":"","title":"Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors","status":"UNKNOWN","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2020-06-01","conditions":"Non Small Cell Lung Cancer, Influenza Vaccine","enrollment":160},{"nctId":"NCT03390166","phase":"PHASE2, PHASE3","title":"Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2017-07-24","conditions":"Influenza","enrollment":945},{"nctId":"NCT02894840","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of GPO Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2015-11","conditions":"Influenza","enrollment":340},{"nctId":"NCT02972957","phase":"PHASE4","title":"A Study of Intranasal Live Attenuated Influenza Vaccine Immunogenicity and Associations With the Nasopharyngeal Microbiome Among Children in the Gambia","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2017-01-30","conditions":"Influenza","enrollment":364},{"nctId":"NCT03293732","phase":"PHASE1","title":"Study of the Safety, Tolerability and Immunogenicity of an Intranasal Influenza Vaccine Administered to Healthy Adults","status":"COMPLETED","sponsor":"Advagene Biopharma Co. Ltd.","startDate":"2012-11-28","conditions":"Flu, Human","enrollment":36},{"nctId":"NCT03056924","phase":"","title":"Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2017-07-05","conditions":"Inflammatory Bowel Diseases","enrollment":173},{"nctId":"NCT02831751","phase":"PHASE2","title":"Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adults","status":"COMPLETED","sponsor":"Medicago","startDate":"2016-04","conditions":"Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases","enrollment":1001},{"nctId":"NCT03467074","phase":"","title":"Role of Interferon-λ and Vaccine Response","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2014-09-01","conditions":"Vaccine Response Impaired, Allogeneic Stem Cell Transplantation","enrollment":200},{"nctId":"NCT04122222","phase":"NA","title":"Immune Response to Influenza Vaccine in ESRD Patients","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2016-08-25","conditions":"Immunology, Nephrology","enrollment":60},{"nctId":"NCT01430689","phase":"PHASE4","title":"Maternal Flu Vaccine Trial in Bamako, Mali","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2011-09-12","conditions":"Influenza","enrollment":4193},{"nctId":"NCT00310804","phase":"PHASE3","title":"Safety and Immunogenicity of 3 Lots of Cell-derived Subunit Influenza Vaccine as Compared to 1 Lot to Egg-derived Subunit Influenza Vaccine in Healthy Adults (>=18 to <=60)","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2005-09","conditions":"Influenza","enrollment":1200},{"nctId":"NCT00306527","phase":"PHASE3","title":"Comparison of Safety, Tolerability and Immunogenicity of Influenza Vaccines in Adults and Elderly","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2005-09","conditions":"Influenza","enrollment":2235},{"nctId":"NCT03095599","phase":"PHASE2, PHASE3","title":"Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S) - PHASE 2/3","status":"COMPLETED","sponsor":"Institute of Vaccines and Medical Biologicals, Vietnam","startDate":"2017-03-20","conditions":"Influenza, Human","enrollment":889},{"nctId":"NCT02438423","phase":"PHASE1","title":"Inactivated Influenza Vaccine Delivered by Microneedle Patch or by Hypodermic Needle","status":"COMPLETED","sponsor":"Mark Prausnitz","startDate":"2015-06","conditions":"Influenza","enrollment":100},{"nctId":"NCT00586469","phase":"PHASE4","title":"A Randomized Study to Compare the Safety and Immunogenicity of Fluviral® Made With New Versus Aged Bulk","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-12-14","conditions":"Influenza Vaccines","enrollment":1000},{"nctId":"NCT00718120","phase":"PHASE3","title":"Immunogenicity and Safety Study of GSK Biologicals' Fluviral® (2008 - 2009 Season) in Adults Over 18 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-07-18","conditions":"Influenza Vaccines","enrollment":110},{"nctId":"NCT01644149","phase":"PHASE4","title":"Clinical Trial Assessing the Immunologic Response to a Influenza Vaccine Delivered Using an Jet Injection Device or a Needle Syringe","status":"COMPLETED","sponsor":"PharmaJet, Inc.","startDate":"2012-01","conditions":"Influenza Prophylaxis","enrollment":83},{"nctId":"NCT01222403","phase":"PHASE4","title":"A Post-marketing Study to Monitor the Safety of a MF59-adjuvanted Influenza Vaccine Administered in Korean Subjects Aged 65 Years or Older","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-10","conditions":"Influenza","enrollment":767},{"nctId":"NCT02256488","phase":"PHASE3","title":"Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2014-09","conditions":"Prophylaxis: Influenza","enrollment":1561},{"nctId":"NCT02935192","phase":"PHASE3","title":"Phase 3 Trial of Serbian Seasonal Influenza Vaccine","status":"COMPLETED","sponsor":"Institute of Virology, Vaccines and Sera, Torlak","startDate":"2016-11-28","conditions":"Influenza","enrollment":480},{"nctId":"NCT03336593","phase":"PHASE2","title":"Protectivity and Safety of Quadrivalent Influenza HA Vaccine in Indonesian Population","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2017-11-21","conditions":"Safety Issues","enrollment":810},{"nctId":"NCT01522248","phase":"NA","title":"Early Immune Responses to Inactivated Influenza Vaccine: a Pilot Study","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2012-01","conditions":"Influenza Virus Vaccine","enrollment":20},{"nctId":"NCT03101462","phase":"PHASE4","title":"Live Attenuated Influenza Vaccine (LAIV) Versus Trivalent Inactivated Influenza Vaccine in Healthy Adults 18-49 Years","status":"COMPLETED","sponsor":"St. Louis University","startDate":"2011-02-24","conditions":"Influenza","enrollment":38}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":47,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Trivalent influenza vaccine A","genericName":"Trivalent influenza vaccine A","companyName":"Shanghai Institute Of Biological Products","companyId":"shanghai-institute-of-biological-products","modality":"Biologic","firstApprovalDate":"","aiSummary":"A trivalent inactivated influenza vaccine that stimulates the immune system to produce antibodies against three strains of influenza virus (typically two A strains and one B strain). Used for Seasonal influenza prevention in adults and children.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}